Nebivolol - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:10Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 15:		Line 15:
	\| legal = Rx-only in US		\| legal = Rx-only in US
	\| mechanism = The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism.		\| mechanism = The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism.
	\| intro = Nebivolol is a third-generation beta blocker with two stereoisomers: d-nebivolol provides highly β1-selective blockade, while l-nebivolol releases endothelial NO and produces direct vasodilation. The result is a favorable side-effect profile relative to older beta blockers — less fatigue, less sexual dysfunction, and even some evidence of improved erectile function. FDA-approved only for hypertension in the US.		\| intro = Nebivolol is a third-generation beta blocker with two stereoisomers: d-nebivolol provides highly β1-selective blockade, while l-nebivolol releases endothelial NO and produces direct vasodilation. The result is a favorable side-effect profile relative to older beta blockers, less fatigue, less sexual dysfunction, and even some evidence of improved erectile function. FDA-approved only for hypertension in the US.
	\| indications =		\| indications =
	\| dosing =		\| dosing =
Line 27:		Line 27:
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring = Heart rate, blood pressure		\| monitoring = Heart rate, blood pressure
	\| counseling = Do not stop abruptly. Tolerated well by many patients who can't tolerate other beta blockers, but the FDA problem is HTN only — off-label use in HF lacks the trial evidence of metoprolol succinate / bisoprolol / carvedilol.		\| counseling = Do not stop abruptly. Tolerated well by many patients who can't tolerate other beta blockers, but the FDA problem is HTN only, off-label use in HF lacks the trial evidence of metoprolol succinate / bisoprolol / carvedilol.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Metoprolol]], [[Bisoprolol]], [[Propranolol]]		\| seealso = [[Metoprolol]], [[Bisoprolol]], [[Propranolol]]

MDElliottMD: Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

2026-05-19T01:37:44Z

Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

← Older revision		Revision as of 01:37, 19 May 2026
Line 27:		Line 27:
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring = Heart rate, blood pressure		\| monitoring = Heart rate, blood pressure
	\| counseling = Do not stop abruptly. Tolerated well by many patients who can't tolerate other beta blockers, but the FDA ~~indication~~ is HTN only — off-label use in HF lacks the trial evidence of metoprolol succinate / bisoprolol / carvedilol.		\| counseling = Do not stop abruptly. Tolerated well by many patients who can't tolerate other beta blockers, but the FDA problem is HTN only — off-label use in HF lacks the trial evidence of metoprolol succinate / bisoprolol / carvedilol.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Metoprolol]], [[Bisoprolol]], [[Propranolol]]		\| seealso = [[Metoprolol]], [[Bisoprolol]], [[Propranolol]]

MDElliottMD: Create Nebivolol scaffold

2026-05-15T07:15:41Z

Create Nebivolol scaffold

New page

{{MedTemplate
| generic = Nebivolol
| brand = Bystolic
| classes = Beta Blocker, Cardioselective (β1) + vasodilator
| uses = <vote slug="hypertension-use">Hypertension</vote>
| starting_dose = 5 mg daily
| preparations = 2.5, 5, 10, 20 mg tabs
| fda_max = 40 mg/d
| routes = Oral
| onset = 1–2 h
| duration = 24 h
| halflife = ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers)
| bioavailability = ~12% (extensive metabolizers); ~96% (poor metabolizers)
| pregnancy = Category C
| legal = Rx-only in US
| mechanism = The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism.
| intro = Nebivolol is a third-generation beta blocker with two stereoisomers: d-nebivolol provides highly β1-selective blockade, while l-nebivolol releases endothelial NO and produces direct vasodilation. The result is a favorable side-effect profile relative to older beta blockers — less fatigue, less sexual dysfunction, and even some evidence of improved erectile function. FDA-approved only for hypertension in the US.
| indications =
| dosing =
| effects =
| pk_absorption = Highly dependent on CYP2D6 phenotype: ~12% in extensive metabolizers, up to ~96% in poor metabolizers.
| pk_distribution = Plasma protein binding ~98%.
| pk_metabolism = Hepatic via CYP2D6 (extensive first-pass in EMs).
| pk_elimination = Renal (38%) and fecal (44%) excretion of metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Heart rate, blood pressure
| counseling = Do not stop abruptly. Tolerated well by many patients who can't tolerate other beta blockers, but the FDA indication is HTN only — off-label use in HF lacks the trial evidence of metoprolol succinate / bisoprolol / carvedilol.
| anecdotes =
| seealso = [[Metoprolol]], [[Bisoprolol]], [[Propranolol]]
| references = <references/>
}}

[[Category:Beta Blockers]]
[[Category:Medicines]]